Protocol for Gene Therapy of the Respiratory Manifestations of Cystic 
Fibrosis Using a Replication Deficient, Recombinant Adenovirus to 
Transfer the Normal Human Cystic Fibrosis Transmembrane 
Conductance Regulator cDNA to the Airway Epithelium 1 
Document prepared for the NIH Recombinant DNA Advisory Committee 
October 7, 1992 
Principal Investigator: Ronald G. Crystal, M.D., Chief, Pulmonary Branch, 
National Heart, Lung, and Blood Institute, Room 6D03 , Building 10, Phone 
301-496-1597, FAX 301-496-2363 
Associate Investigators: Ari Jaffe, M.D. , Senior Investigator, Pulmonary 
Branch; Steve Brody, M.D. , Senior Investigator, Pulmonary Branch; Andrea 
Mastrangeli, M.D., Senior Investigator, Pulmonary Branch; Noel G. McElvaney, 
M.D. , Senior Investigator, Pulmonary Branch; Melissa Rosenfeld, M.D. , Senior 
Investigator, Pulmonary Branch; Chin-Shyan Chu, M.D., Senior Investigator, 
Pulmonary Branch; Claire Danel, M.D. , Special Volunteer, Pulmonary Branch; 
John Hay, M.D, Visiting Associate, Pulmonary Branch; Tony Eissa, M.D., Senior 
Staff Fellow, Pulmonary Branch; Thomas M. Horiagon, M.D., Special Volunteer, 
Pulmonary Branch. 
1 The protocol is also being considered by the Food and Drug Administration as 
an Investigational New Drug Application from the Pulmonary Branch, National 
Heart, Lung, and Blood Institute, Ronald G. Crystal, M.D., Principal 
Investigator . 
[616] 
Recombinant DNA Research, Volume 16 
